In this article, we highlight three recent studies that showcase the power of methylation screening for the diagnosis and prognostic measurement of different types of
Review performance of duet multiomics solution +modC for the detection of genetic and epigenetic sequence data at base resolution when using formalin damaged DNA. Samples include formalin-compromised DNA standards (fcDNA) as well as DNA extracted from formalin-fixed and paraffin-embedded (FFPE) samples of two colorectal cancer (CRC) patients.
biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single
It all started with an epigenetic discovery Since Cambridge Epigenetix began in 2012, we’ve been innovating in the field of DNA sequencing and epigenetics. Back
Representatives from our R&D team presented 3 posters at the Advances in Genome Biology & Technology General Meeting in Hollywood, Florida.
We are extremely proud to announce that our paper ‘Simultaneous sequencing of genetic and epigenetic bases in DNA’ has been published by the journal Nature Biotechnology.
We had the opportunity to speak with Dr. Gary Yalloway and Dr. Julia Vivian, Senior Scientists at Cambridge Epigenetix on LM20 Microfluidizer®.
CEGX CSO Joanna Holbrook recently appeared on Precision Medicine Forum Podcast
Innovative Cancer Science ‘CEGX scientists discussed novel sequencing technology for early cancer detection’
Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health
